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INTRODUCTION
Upper tract urothelial carcinoma (UTUC) is a rare 
malignancy, with a reported annual incidence in the 
Western literature of  2 per 100,000 persons [1]. Despite 
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Purpose: To evaluate the impact of adjuvant chemotherapy (AC) in patients with upper tract urothelial carcinoma and lymphovas-
cular invasion (LVI) after radical nephroureterectomy (RNU).
Materials and Methods: We retrospectively analyzed the clinical records and clinicopatholgic outcomes of patients (n=552) 
treated with RNU between 1986 and 2013. Patients treated with neoadjuvant chemotherapy and those for whom LVI status was 
not recorded were excluded. Patients were divided into two groups according to LVI (n=86) or no LVI (n=256).
Results: The study included 344 patients (240 men and 104 women) with a median of 53.9 months of follow-up (range, 1–297 
months) after RNU. Tumors were organ conﬁned (T2/N0) in 211 (61.3%) and tumor grade high in 291 (84.6%). AC was adminis-
tered in 64 patients (18.6%). A total of 280 patients (81.4%) were treated with surgery alone. Patients with LVI tended to be older 
(p=0.049), have a higher pT stage (pT3/T4, p<0.001), be pN+ (p<0.001), have a high tumor grade (p<0.001), and experience re-
currence (p<0.001). In the multivariate analysis, LVI was an independent prognostic factor for cancer-specific survival and overall 
survival (p=0.002 and p<0.001, respectively). The multivariate analysis demonstrated that in the subgroup of patients with LVI, AC 
was a significant prognostic factor for cancer-specific survival and overall survival (hazard ratio, 0.51; p=0.027 and hazard ratio, 0.50; 
p=0.025, respectively).
Conclusions: AC does not seem to reduce mortality in patients with advanced upper tract urothelial carcinoma after RNU. In the 
subgroup of patients with LVI, AC had a positive impact on cancer-specific survival and overall survival. LVI would be helpful for 
selecting patients who are appropriate for AC.
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advances in endoscopic and minimally invasive treatments 
during the past two decades, UTUC continues to portend 
a poor prognosis, with approximately 28% of  patients 
experiencing a recurrence of  disease outside the bladder 
and 23% of patients dying of the disease within 5 years [2].
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted 
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
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Although advanced UTUC is associated with poor 
oncologic outcomes, there is no standardized therapy 
conferring a survival benef it af ter radical nephro­
ureterectomy (RNU). Currently, no randomized trials that 
have investigated the role of  adjuvant chemotherapy 
(AC) for UTUC exist, and there is insufficient evidence 
to integrate neoadjuvant chemotherapy or AC into a 
treatment strategy for advanced UTUC. The majority of 
the available data are from retrospective analyses and 
the results have been inconclusive [3­6]. A recent meta­
analysis showed that cisplatin­based AC was beneficial in 
terms of overall survival (OS) and disease­specific survival; 
however, the results were also limited by the relatively 
small sample size and the retrospective nature of  the 
studies included in the analysis [7].
Numerous studies have investigated prognostic factors 
in patients with UTUC, and tumor stage and tumor grade 
have been reported to be the most significant prognostic 
factors [3­5]. In addition, lymphovacular invasion (LVI) 
has been demonstrated as a predictor of  poor prognosis 
in several studies [8­14]. Moreover, the latest European 
guidelines on UTUCs suggested LVI as an independent 
predictor of  survival [15]. In our previous study, we also 
reported that LVI was a significant prognostic factor 
for recurrence­free and cancer­specific survival (CSS) in 
patients with UTUC [9]. In this study, we extended our 
previous UTUC cohort and investigated whether AC 
improved survival in patients with UTUC and LVI.
MATERIALS AND METHODS
Patient information was retrospectively collected 
from a database approved by the Yonsei University 
Institutional Review Board. A review of medical records of 
our institute identified 552 patients with primary UTUC 
who underwent RNU between 1986 and 2013. We excluded 
181 patients who had incomplete data on LVI and 27 
patients treated with neoadjuvant chemotherapy. Thus, a 
total of 344 patients were included in our study. 
Each patient underwent preoperative evaluation, 
including blood test, urine cytology, cystoscopy, chest x­ray, 
abdominopelvic computed tomography, and bone scan. 
Clinicopathological variables including age, gender, tumor 
stage, tumor grade, tumor location, and LVI status were 
investigated. 
All surgical specimens were analyzed by uropathologists 
of our institution. Tumor grades were assessed according 
to the 1998 World Health Organization/International 
Society of Urologic Pathology consensus classification [16]. 
Staging was performed according to the American Joint 
Committee on Cancer system [17]. LVI was defined as the 
unequivocal presence of cancer cells in endothelium­lined 
lymphatic and vascular channels without underlying 
muscular walls [18]. Routine light microscopic examination 
with hematoxylin and eosin was performed; no immuno­
histochemical staining was used to identify LVI.
Postoperative follow­up was performed every 3 months 
for 2 years, and then every 6 months thereafter. Follow­up 
included history, physical examination, serum chemistry 
studies, urinary cytology, chest radiography, cystoscopic 
evaluation of the bladder, and radiographic evaluation of 
the contralateral upper urinary tract.
The cause of  death was corroborated by reviewing 
the charts. Death certificates were used to assess cause of 
death.
Patients treated with at least one cycle of chemotherapy 
within 3 months af ter RNU were regarded to have 
received AC based on pathological stage pT3 or greater 
or node positivity. Two types of  platinum­based chemo­
therapies were used: methotrexate, vinblastine, doxorubicin 
(Adriamycin), and cisplatin (MVAC) or gemcitabine and 
cisplatin (GC). Cisplatin was substituted with carboplatin 
if  the glomerular filtration rate was between 30 and 49 
mL/min. The treatment protocols and follow­up schedules 
were surgeon­dependent. There was no routine restaging 
postoperatively before AC. 
Patients were stratified into two groups in accordance 
with the presence of LVI, and clinicopathological features 
were compared between the two groups. Qualitative 
variables were compared by using a chi­square test and 
quantitative variables were compared by using Student 
t­test. The prognostic significance of LVI was examined in 
the entire cohort and we also evaluated whether AC was 
independently associated with OS and CSS in accordance 
with the presence of  LVI. Univariate and multivariate 
Cox’s proportional hazard regression models were used to 
identify the independent parameters associated with OS 
and CSS. 
All reported p­values were two­sided, and a p­value of 
≤0.05 was considered to indicate statistical significance. All 
statistical tests were carried out with IBM SPSS Statistics 
ver. 20.0 (IBM Co., Armonk, NY, USA).
RESULTS
Patients were divided into two groups according to the 
presence of LVI: group 1 (n=86, LVI (+)) and group 2 (n=258, 
LVI (–)). Patients with LVI were significantly older and 
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had higher pathologic stage and tumor grade (Table 
1). The 5­year OS and CSS rates were 31.0% and 45.0%, 
respectively. OS and CSS were lower in patients with LVI 
than in patients without LVI (p<0.001, Fig. 1A; p<0.001, Fig. 
1B, respectively). 
Of  the 344 patients, 64 (18.6%) received AC and 280 
(81.4%) were treated with surgery alone. Also, LVI was 
independently associated with worse CSS and OS after 
adjustment for age, gender, pathologic stage, and tumor 
grade. In the entire cohort, AC was not independently 
associated with survival (CSS, p=0.161; OS, p=0.144) (Table 
2). In patients with LVI (group 1), AC was independently 
associated with improved CSS (hazard ratio [HR], 0.51; 
p=0.027) and OS (HR, 0.50; p=0.025) after adjustment for 
Fig. 1. Impact of lymphovascular invasion (LVI) in cancer-specific (A) and overall survivals (B) in patients with upper urinary tract transitional cell carci-
noma.
Table 1. Clinical and pathological characteristics of 344 patients according to LVI
Characteristic Total (n=344)
Group 1 (n=86) Group 2 (n=258)
p-value
LVI (+) LVI (–)
Age (y) 65.06±10.57 67.00±9.04 64.41±10.98 0.049 
Sex
 Male 240 (69.8) 59 (68.6) 181 (70.2) 0.787
 Female 104 (30.2) 27 (31.4) 77 (29.8)
pT stage <0.001
 Ta/T1 86 (25.0) 5 (5.8) 81 (31.4)
 T2 58 (16.9) 10 (11.6) 48 (18.6)
 T3 172 (50.0) 60 (69.8) 112 (43.4)
 T4 28 (8.1) 11 (12.8) 17 (6.6)
pN stage <0.001
 Nx or N0 265 (77.0) 50 (58.1) 215 (83.3)
 N+ 79 (23.0) 36 (41.9) 43 (16.7)
Grade <0.001
 Low 53 (15.4) 2 (2.3) 51 (19.8)
 High 291 (84.6) 84 (97.7) 207 (80.2)
Location 0.895 
 Renal pelvis 146 (42.4) 38 (44.2) 108 (41.9)
 Ureter 147 (42.7) 33 (38.4) 114 (44.2)
 Both 51 (14.8) 15 (17.4) 36 (14.0)
Adjuvant chemotherapy <0.001
 Yes 64 (18.6) 35 (40.7) 29 (11.2)
 No 280 (81.4) 51 (59.3) 229 (88.8)
Values are presented as mean±standard deviation or number (%).
LVI, lymphovascular invasion.
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other variables (Table 3). In patients without LVI (group 2), 
AC was not significantly associated with survival and had 
no impact on CSS or OS (Table 3). 
Patients with LVI were further stratified by patho­
logical stage (pT1­2 vs. pT3­4) and we further evaluated 
the impact of AC. A favorable impact of AC on CSS and 
OS was found in patients with pT3­4 and LVI but not 
in patients with pT1­2 and LVI in the univariate Cox’s 
proportional hazard regression analyses (Table 4). In 
patients with pT3­4, AC was not significantly associated 
with CSS or OS in the univariate or multivariate analysis 
(data not shown).
DISCUSSION
We analyzed clinicopathologic features and survival 
outcomes of  patients treated with RNU for UTUC over 
two decades. AC was not significantly associated with CSS 
or OS in all patients.  However, AC was independently 
associated with CSS and OS in patients with LVI. 
Specifically, there was a significant difference in survival 
after AC in patients with T3­4 and LVI but not in those 
with T1­2 and LVI.
There is no standardized chemotherapy conferring a 
survival benefit after RNU. Although UTUC is similar 
morphologically to lower tract urothelial carcinoma, 
there are occasional phenotypic and genotypic differences 
[7]. Therefore, these f indings suggest a dif ference in 
chemotherapy response between UTUC and lower tract 
urothelial carcinoma. Nevertheless, many clinicians treat 
patients with high­risk UTUC with AC. Several platinum­
based regimens have been proposed, although AC protocols 
are not standardized. The efficacy of platinum­based AC 
was expected to be similar to that seen in bladder cancer 
because of similarities in the pathological features. Clinical 
decision­making regarding AC is dependent on multiple 
factors such as performance and impaired renal function 
after RNU. Urologists should consider that most patients 
with AC underwent cisplatin­based chemotherapy with 
nephrotoxicity. 
The prospective randomized controlled perioperative 
chemotherapy versus surveillance in upper tract urothelial 
cancer (POUT) trial has enrolled patients with UTUC 
staged pT2­pT4 N0­3 M0 or pTany N1­3 M0 after RNU 
starting in 2012 [17]. Until the results of the POUT trial 
are revealed, the efficacy of  AC after RNU will remain 
controversial. However, although there is no well­powered 
level 1 evidence to support AC for advanced UTUC, several 
studies have examined the role of  AC. Kwak et al. [3] 
suggested that in a multivariable Cox proportional hazard 
analysis of  43 patients with UTUC, AC was strongly 
associated with OS. Another recent study reported that 
cisplatin­based AC for UTUC had no influence on CSS; 
however, AC can reduce bladder recurrence [4]. Lucca et 
al. [6] showed that only patients at the highest risk for 
disease recurrence with pT3/T4 N+ disease may benefit 
from AC. A recent retrospective analysis suggested that 
AC had no survival benefit for CSS and OS in patients 
with advanced UTUC (pT3N0, pT4N0, and/or lymph node 
positive) [5]. 
Our study showed that there was no signif icant 
dif ference in CSS or OS between an AC group and a 
no–adjuvant­chemotherapy group. However, this study 
presents a favorable response to AC in patients with LVI+ 
Table 2. Univariatate and multivariate analyses predicting CSS and OS in patients with UTUC after RNU
Variable
CSS OS
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age* 1.02 (1.006–1.038) 0.007 1.02 (1.001–1.035) 0.040 1.02 (1.008–1.037) 0.003 1.02 (1.003–1.033) 0.022
Sex (female vs. male) 1.08 (0.78–1.507) 0.627 1.05 (0.775–1.427) 0.746
pT stage 
 Ta/T1/T2 Reference - Reference - Reference - Reference -
 T3/T4 4.39 (2.955–6.529) <0.001 2.88 (1.892–4.390) <0.001 2.54 (1.849–3.485) <0.001 1.84 (1.309–2.592) <0.001
 pN stage  
(N+ vs. Nx/N0)
3.71 (2.677–5.130) <0.001 2.27 (1.611–3.186) <0.001 3.09 (2.259–4.222) <0.001 2.08 (1.492–2.907) <0.001
 Grade (high vs. low) 2.99 (1.660–5.382) <0.001 2.09 (1.142–3.806) 0.017 1.67 (1.085–2.556) 0.020 1.26 (0.810–1.967) 0.304
 LVI (LVI+ vs. LVI–) 3.04 (2.171–4.247) <0.001 1.75 (1.229–2.471) 0.002 2.64 (1.909–3.641) <0.001 1.83 (1.311–2.565) <0.001
 AC (yes vs. no) 1.90 (1.306–2.765) <0.001 0.74 (0.490–1.126) 0.161 1.64 (1.134–2.367) 0.009 0.74 (0.488–1.110) 0.144
CSS, cancer-specific survival; OS, overall survival; UTUC, upper tract urothelial carcinoma; RNU, radical nephroureterectomy; HR, hazard ratio; CI, 
confidence interval; LVI, lymphovascular invasion; AC, adjuvant chemotherapy.
*At the time of surgery.
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and pT3­pT4N0/x. A recent meta­analysis investigating AC 
for UTUC found an OS and disease­free survival benefit 
among patients treated with cisplatin­based AC compared 
with those who had surgery alone [7]. Established studies 
have shown that AC is not significantly associated with 
outcomes of patients with lymph­node­positive disease. We 
found that AC was effective in patients with high­risk 
UTUC and LVI. AC reduced the relative risk of  UTUC­
related CSS by 50% (HR, 0.50; p=0.025). However, these 
studies suffer from selection biases in which high­risk 
patients are selected to receive AC compared with their 
counterparts who undergo observation. 
Several studies have reported that LVI is a significant 
prognostic factor in patients with UTUC as well as 
other urologic malignancies. Recent studies reported the 
significance of LVI for bladder cancer. LVI was strongly 
associated with lymph node invasion because of  the 
presence of  circulating cancer cells and the formation 
of  micrometastasis, which suggested LVI as a predictor 
of  poor prognosis [8,19]. Our previous study reported 
that LVI was significantly associated with recurrence­
free survival or CSS in patients who had only localized 
UTUC (pTa­3N0M0) [9]. This study showed that LVI was 
independently associated with worse CSS and OS after 
adjustment for age, gender, pathologic stage, and tumor 
grade. A meta­analysis confirmed that patients with LVI 
were associated with LN metastases and suggested an 
opportunity for identifying patients for AC. 
Hurel et al. [11] showed that the incidence of LVI (+) 
was slightly higher (29.6%) than previously described, 
because they did not classify unknown LVI status as LVI 
(–). In pathologic reports, LVI status was not routinely 
described. In previous studies, LVI was detected in –15% 
to 20% of  cases [10]. In our study, we excluded patients 
without LVI status in pathologic reports. The incidence of 
LVI (+) was 25.0%. 
This study had limitations. Several characteristics could 
account for the heterogeneity in the results, including 
the small size cohort, the multiple physicians, and the 
variability of  intraoperative management. Heterogeneity 
of  patients treated with AC existed. Multiple factors 
influenced the clinical decision making regarding the 
use of  AC such as age, performance status, and renal 
function. Although AC regimens in the study cohort were 
not standardized, cisplatin­based chemotherapy was used 
for the standard AC regimen. We analyzed the impact of 
AC by including all 3 regimens and comparison between 
regimens was not performed.
Another limitation was the extent of  lymph node 
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dissection. pN stage and lymph node dissection may 
influence the decision­making regarding AC. However, 
in our study, regional lymph node dissection was not 
routinely performed in patients with clinically apparent 
lymphadenopathy on preoperative radiologic imaging or 
lymphadenopathies found intraoperatively.
Finally, the practice to demonstrate LVI status was 
performed only for select cases suspicious for invasion 
across the study period. Although the patients without 
LVI status were excluded and our incidence of  LVI is 
similar to previous results, the potential for selection bias 
exists. 
Despite the limitations of our study, we demonstrated 
that AC improved oncologic outcomes in patients with 
LVI who underwent RNU for UTUC. We expect a large, 
prospective randomized investigation to verify our 
conclusions.
CONCLUSIONS
In the current study, LVI and pT stage were signi­
ficant prognostic factors for CSS and OS in patients with 
UTUC. The subgroup of patients with T3­4 and LVI is the 
target population for AC.
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